Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Income from Continuing Operations of 37094432.0 in Q1 2026, down 151.01% quarter-over-quarter from 72715485.96 in Q4 2025, and little changed on a YoY basis from 37264809.33 in Q1 2025.
Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Oculis Holding AG's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 37094432.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations changed 0.46% year-over-year to 37094432.0; the TTM figure through Mar 2026 stood at 21033180158.89 (up 9.94% YoY), while the FY2025 annual figure was 124277444.25, down 26.45% from the prior year.
- Income from Continuing Operations was 37094432.0 for Q1 2026 at Oculis Holding AG, down from 72715485.96 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 72715485.96 in Q4 2025 to a low of 23261892784.97 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 2783551865.92 across 5 years, with a median of 21477057.43 in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 116344.35% in 2024, then surged 318.67% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 9561219.83 in 2022, then plunged by 47.68% to 14120114.78 in 2023, then sank by 135.51% to 33253672.96 in 2024, then soared by 318.67% to 72715485.96 in 2025, then plunged by 151.01% to 37094432.0 in 2026.
- The last three Income from Continuing Operations figures came in at 37094432.0 (Q1 2026), 72715485.96 (Q4 2025), and 21038093019.56 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -37.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.09 Mn |
| Dec 31, 2025 | 72.72 Mn |
| Sep 30, 2025 | -21.04 Bn |
| Jun 30, 2025 | -30.71 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -33.25 Mn |
| Sep 30, 2024 | -23.26 Bn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -18.37 Mn |
| Dec 31, 2023 | -14.12 Mn |
| Sep 30, 2023 | -19.98 Mn |
| Jun 30, 2023 | -14.07 Mn |
| Mar 31, 2023 | -49.48 Mn |
| Dec 31, 2022 | -9.56 Mn |
| Sep 30, 2022 | -10.29 Mn |
| Jun 30, 2022 | -12.73 Mn |